Brief: Scope Fluidics SPV Signs Deal To Assess Clinical Effectiveness Of PCR|ONE Panel SARS-CoV-2
17/08/2020 09:27
Aug 17 (Reuters) - Scope Fluidics SA SCPP.WA :
* SAYS ITS SPV SIGNS DEAL WITH KRZYSZTOF PYRC TO ASSESS
CLINICAL
EFFECTIVENESS OF PCR|ONE PANEL SARS-COV-2 UNDER FDA EMERGENCY
USE AUTHORISATION PROCEDURE
Source text for Eikon: ID:nEM6pmll2a
Further company coverage: SCPP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Scope Fluidics SA
See all newsBrief: Scope Fluidics Extends Deadline For First Milestone Of Hybolic Project To End Of Q3 2026
Brief: Scope Fluidics Says Bacteromic Granted U.S. Patent 'Microfluidic Chip'
Brief: Scope Fluidics Q1 Net Loss At 13.5 Million Zlotys
Brief: Scope Fluidics Unit Bacteromic Starts Collaboration With US Research Center For FDA Registration Trials
Brief: Scope Fluidics FY Net Loss At 46.4 Million Zlotys